Skip to content
sellWeak cluster of 210b5-1 plan

Parisi Samuel Joseph sold $132k of ALKS

VP, Finance (Interim PAO) at Alkermes plc.. 3,743 shares at an average of $35.26, traded Feb 25, 2025, filed Feb 25, 2025.

Warning score
9
Value
$132k
3,743 shares
Holdings after
7,717
-33% from before
From 52-week low
+36%
low $25.70, close $34.93
From 52-week high
-3%
high $36.00, as of Feb 25, 2025

Score components

The components behind this score (role, size, price context, cluster, track record, modifiers) are shown to Pro users. Start with Pro

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price, last year

ALKS, daily close, last year. insider buy insider sellDot size follows the dollar value (largest $132k).

Rows in this filing

Every transaction in Form 4 0001127602-25-006722, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 22, 2025MOption exercise
Ordinary Shares10b5-1
+3,114--10,831Feb 25, 2025
Feb 22, 2025FTax withholding
Ordinary Shares10b5-1
-983$35.32$35k9,848Feb 25, 2025
Feb 23, 2025MOption exercise
Ordinary Shares10b5-1
+2,284--12,132Feb 25, 2025
Feb 23, 2025FTax withholding
Ordinary Shares10b5-1
-672$35.32$24k11,460Feb 25, 2025
Feb 25, 2025SOpen-market sale
Ordinary Shares10b5-1
-3,743$35.26$132k7,717Feb 25, 2025
Feb 22, 2025MOption exercise
Restricted Stock Unit Awardderivative10b5-1
-3,114--0Feb 25, 2025
Feb 23, 2025MOption exercise
Restricted Stock Unit Awardderivative10b5-1
-2,284--4,567Feb 25, 2025

Related signals

Other insiders at Alkermes plc. and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
0Weaksell10b5-1ALKS
Alkermes plc.
Parisi Samuel Joseph
VP, Finance (Interim PAO)
$66k1,938
0Weaksell 210b5-1ALKS
Alkermes plc.
Parisi Samuel Joseph
VP, Finance (Interim PAO)
$47k1,327
33Weaksell 210b5-1ALKS
Alkermes plc.
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
$12M349,340
25Weaksell10b5-1ALKS
Alkermes plc.
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
$3.2M100,918
9Weaksell 310b5-1ALKS
Alkermes plc.
LAURENCIN CATO T
director
$86k2,691
40Moderatesell 310b5-1ALKS
Alkermes plc.
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
$2.0M61,151
29Weaksell 310b5-1ALKS
Alkermes plc.
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
$290k9,221
32Weaksell 310b5-1ALKS
Alkermes plc.
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
$442k14,349
21Weaksell 310b5-1ALKS
Alkermes plc.
Nichols Christian Todd
SVP, Chief Commercial Officer
$152k5,208
15Weaksell10b5-1ALKS
Alkermes plc.
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
$1.8M58,996

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Parisi Samuel Joseph sold $132k of ALKS | InsiderTell